Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

ABSTRACT:

Background

In Canada and elsewhere, pazopanib and sunitinib-tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors-are recommended as first-line treatment for patients with metastatic renal cell carcinoma (mrcc). A large randomized noninferiority trial of pazopanib versus sunitinib (comparz) demonstrated that the two drugs have similar efficacy; however, patients randomized to pazopanib experienced better health-related quality of life (hrqol) and nominally lower rates of non-study medical resource utilization.

Methods

The cost-effectiveness of pazopanib compared with sunitinib for first-line treatment of mrcc from a Canadian health care system perspective was evaluated using a partitioned-survival model that incorporated data from comparz and

SUBMITTER: Amdahl J 

PROVIDER: S-EPMC4974040 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature